organization · Reporting owner
Ute Holdings, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nexvet Biopharma plc
Report date July 31, 2017 · Filed August 02, 2017
Jointly reported with FARALLON CAPITAL MANAGEMENT, L.L.C., FARALLON PARTNERS L L C/CA, Akubra Investors, LLC, Bushranger Funding, LLC, Farallon AA G.P., L.L.C., Farallon Partners GP VI, L.L.C., NGP, L.L.C., Dreyfuss Philip D, Fisch Michael B.
Section 16 reporting ended · disclosed 2017-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-07-31 · Other · Disposed 833,845 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F3: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra"). |
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-07-31 · Other · Disposed 899,268 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F4: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger"). |
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-07-31 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2017-07-31 · Other · Disposed 915,583 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F5: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2017-07-31 · Other · Disposed 122,006 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F3: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra"). F7: The members of Akubra are FCIP XR 2014, L.L.C. ("FCIP XR") and Noonday Special Situation Partners, L.P. ("NSSP") (each, a "Farallon Akubra Fund"). As the general partner of NSSP, NGP, L.L.C. (the "NSSP General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by NSSP as a Farallon Akubra Fund. The NSSP General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra. F8: As the manager of the NSSP General Partner, Farallon Capital Management, L.L.C. (the "Management Company") may be deemed to be a beneficial owner of the Issuer's securities held by NSSP as a Farallon Akubra Fund. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2017-07-31 · Other · Disposed 249,462 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F4: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger"). F9: The members of Bushranger are FCP XR 2014, L.L.C. ("FCP XR"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), and Farallon Capital AA Investors, L.P. ("FCAAI") (collectively, the "Farallon Bushranger Funds"). As the general partner of FCAAI, Farallon AA GP, L.L.C. (the "FCAAI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCAAI as a Farallon Bushranger Fund. The FCAAI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Bushranger. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2017-07-31 · Other · Disposed 209,577 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F5: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs"). F10: The members of Ute are FCOI II SS 2014, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners II, L.P. ("FCIP II"), and Farallon Special Situation Partners VI, L.P. ("FSSP VI") (collectively, the "Farallon Ute Funds"). As the general partner of FSSP VI, Farallon Partners GP VI, L.L.C. (the "FSSP VI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FSSP VI as a Farallon Ute Fund. The FSSP VI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Ute. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2017-07-31 · Other · Disposed 2,067,651 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F11: As the general partner of each of (a) the sole member of FCIP XR, (b) the sole member of FCP XR, (c) FCIP III, (d) the sole member of FCOI II SS and (e) FCIP II, Farallon Partners, L.L.C. (the "Farallon General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCIP XR as a Farallon Akubra Fund, FCP XR and FCIP III as Farallon Bushranger Funds, and FCOI II SS and FCIP II as Farallon Ute Funds. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, the Farallon SPVs. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2017-07-31 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2017-07-31 · Other · Disposed 2,648,696 · Balance 0 F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F6: The amount of securities shown in this row is owned directly by the Farallon SPVs. F12: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Monica R. Landry, Michael G. Linn, Ravi K. Paidipaty, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, John R. Warren and Mark C. Wehrly (collectively, the "Managing Members") and Andrew J. M. Spokes (the "Senior Managing Member"), as Managing Members or the Senior Managing Member, as the case may be, of both the Farallon General Partner and the Management Company, and as a manager or senior manager, as the case may be, of both the FCAAI GP and the FSSP VI GP, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by the Farallon SPVs. Each of the Managing Members and the Senior Managing Member disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his or her pecuniary interest, if any. F13: As a director of the Issuer, Patel is filing a separate Form 4 on the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group.
F2: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4.
F3: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra").
F4: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger").
F5: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs").
F6: The amount of securities shown in this row is owned directly by the Farallon SPVs.
F7: The members of Akubra are FCIP XR 2014, L.L.C. ("FCIP XR") and Noonday Special Situation Partners, L.P. ("NSSP") (each, a "Farallon Akubra Fund"). As the general partner of NSSP, NGP, L.L.C. (the "NSSP General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by NSSP as a Farallon Akubra Fund. The NSSP General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra.
F8: As the manager of the NSSP General Partner, Farallon Capital Management, L.L.C. (the "Management Company") may be deemed to be a beneficial owner of the Issuer's securities held by NSSP as a Farallon Akubra Fund. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra.
F9: The members of Bushranger are FCP XR 2014, L.L.C. ("FCP XR"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), and Farallon Capital AA Investors, L.P. ("FCAAI") (collectively, the "Farallon Bushranger Funds"). As the general partner of FCAAI, Farallon AA GP, L.L.C. (the "FCAAI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCAAI as a Farallon Bushranger Fund. The FCAAI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Bushranger.
F10: The members of Ute are FCOI II SS 2014, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners II, L.P. ("FCIP II"), and Farallon Special Situation Partners VI, L.P. ("FSSP VI") (collectively, the "Farallon Ute Funds"). As the general partner of FSSP VI, Farallon Partners GP VI, L.L.C. (the "FSSP VI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FSSP VI as a Farallon Ute Fund. The FSSP VI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Ute.
F11: As the general partner of each of (a) the sole member of FCIP XR, (b) the sole member of FCP XR, (c) FCIP III, (d) the sole member of FCOI II SS and (e) FCIP II, Farallon Partners, L.L.C. (the "Farallon General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCIP XR as a Farallon Akubra Fund, FCP XR and FCIP III as Farallon Bushranger Funds, and FCOI II SS and FCIP II as Farallon Ute Funds. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, the Farallon SPVs.
F12: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Monica R. Landry, Michael G. Linn, Ravi K. Paidipaty, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, John R. Warren and Mark C. Wehrly (collectively, the "Managing Members") and Andrew J. M. Spokes (the "Senior Managing Member"), as Managing Members or the Senior Managing Member, as the case may be, of both the Farallon General Partner and the Management Company, and as a manager or senior manager, as the case may be, of both the FCAAI GP and the FSSP VI GP, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by the Farallon SPVs. Each of the Managing Members and the Senior Managing Member disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his or her pecuniary interest, if any.
F13: As a director of the Issuer, Patel is filing a separate Form 4 on the date hereof.
F14: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 2,648,696 | $6.72 | $17,799,237.12 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 8 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F6 · ownership.nature: The amount of securities shown in this row is owned directly by the Farallon SPVs. F12 · ownership.nature: Each of Philip D. Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Monica R. Landry, Michael G. Linn, Ravi K. Paidipaty, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, John R. Warren and Mark C. Wehrly (collectively, the "Managing Members") and Andrew J. M. Spokes (the "Senior Managing Member"), as Managing Members or the Senior Managing Member, as the case may be, of both the Farallon General Partner and the Management Company, and as a manager or senior manager, as the case may be, of both the FCAAI GP and the FSSP VI GP, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of the Issuer's securities held by the Farallon SPVs. Each of the Managing Members and the Senior Managing Member disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except to the extent of his or her pecuniary interest, if any. F13 · ownership.nature: As a director of the Issuer, Patel is filing a separate Form 4 on the date hereof. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 2,067,651 | $6.72 | $13,894,614.72 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 7 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F11 · ownership.nature: As the general partner of each of (a) the sole member of FCIP XR, (b) the sole member of FCP XR, (c) FCIP III, (d) the sole member of FCOI II SS and (e) FCIP II, Farallon Partners, L.L.C. (the "Farallon General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCIP XR as a Farallon Akubra Fund, FCP XR and FCIP III as Farallon Bushranger Funds, and FCOI II SS and FCIP II as Farallon Ute Funds. The Farallon General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, the Farallon SPVs. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 209,577 | $6.72 | $1,408,357.44 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 6 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F5 · ownership.nature: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs"). F10 · ownership.nature: The members of Ute are FCOI II SS 2014, Ltd. ("FCOI II SS"), Farallon Capital Institutional Partners II, L.P. ("FCIP II"), and Farallon Special Situation Partners VI, L.P. ("FSSP VI") (collectively, the "Farallon Ute Funds"). As the general partner of FSSP VI, Farallon Partners GP VI, L.L.C. (the "FSSP VI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FSSP VI as a Farallon Ute Fund. The FSSP VI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Ute. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 249,462 | $6.72 | $1,676,384.64 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 5 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F4 · ownership.nature: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger"). F9 · ownership.nature: The members of Bushranger are FCP XR 2014, L.L.C. ("FCP XR"), Farallon Capital Institutional Partners III, L.P. ("FCIP III"), and Farallon Capital AA Investors, L.P. ("FCAAI") (collectively, the "Farallon Bushranger Funds"). As the general partner of FCAAI, Farallon AA GP, L.L.C. (the "FCAAI GP") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by FCAAI as a Farallon Bushranger Fund. The FCAAI GP disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Bushranger. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 122,006 | $6.72 | $819,880.32 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 4 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.nature: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.nature: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F3 · ownership.nature: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra"). F7 · ownership.nature: The members of Akubra are FCIP XR 2014, L.L.C. ("FCIP XR") and Noonday Special Situation Partners, L.P. ("NSSP") (each, a "Farallon Akubra Fund"). As the general partner of NSSP, NGP, L.L.C. (the "NSSP General Partner") may be deemed to be a beneficial owner of the Issuer's securities indirectly held by NSSP as a Farallon Akubra Fund. The NSSP General Partner disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "'34 Act"), or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra. F8 · ownership.nature: As the manager of the NSSP General Partner, Farallon Capital Management, L.L.C. (the "Management Company") may be deemed to be a beneficial owner of the Issuer's securities held by NSSP as a Farallon Akubra Fund. The Management Company disclaims any beneficial ownership of any of the Issuer's securities reported or noted herein for purposes of Section 16 of the '34 Act or otherwise, except as to securities representing its pro rata interest in, and interest in the profits of, Akubra. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 915,583 | $6.72 | $6,152,717.76 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 3 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.direct: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F5 · ownership.direct: The amount of securities shown in this row is owned directly by Ute Holdings, LLC ("Ute" and, together with Akubra and Bushranger, the "Farallon SPVs"). Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 899,268 | $6.72 | $6,043,080.96 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 2 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.direct: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F4 · ownership.direct: The amount of securities shown in this row is owned directly by Bushranger Funding, LLC ("Bushranger"). Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 19:54 UTC | Nexvet Biopharma plc NVET · Entity 174046 | OtherOrdinary Shares | 833,845 | $6.72 | $5,603,438.40 |
DisclosureSEC source: 0001182489-17-000447 · edgar.xml · nonDerivative · entry 1 FARALLON CAPITAL MANAGEMENT LLC · CIK 0000909661 · 10% owner · Member of Group Owning 10% FARALLON PARTNERS L L C/CA · CIK 0001040153 · 10% owner · Member of Group Owning 10% Akubra Investors, LLC · CIK 0001632596 · 10% owner · Member of Group Owning 10% Bushranger Funding, LLC · CIK 0001632625 · 10% owner · Member of Group Owning 10% Ute Holdings, LLC · CIK 0001632627 · 10% owner · Member of Group Owning 10% Farallon AA G.P., L.L.C. · CIK 0001632734 · 10% owner · Member of Group Owning 10% Farallon Partners GP VI, L.L.C. · CIK 0001632735 · 10% owner · Member of Group Owning 10% NGP, L.L.C. · CIK 0001632660 · 10% owner · Member of Group Owning 10% Dreyfuss Philip D · CIK 0001693981 · 10% owner · Member of Group Owning 10% Fisch Michael B. · CIK 0001611816 · 10% owner · Member of Group Owning 10% Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F14 · price: Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). F1 · ownership.direct: The entities and individuals identified in the footnotes of this Form 4 may be deemed members of a group holding equity securities of the Issuer. The filing of this Form 4 and any statements included herein shall not be deemed to be an admission that such entities and individuals are members of such group. F2 · ownership.direct: Since the number of reporting persons that may be listed on a Form 4 is limited, the entities and individuals listed in these footnotes that are not reporting persons on this Form 4 are filing additional Forms 4 on the date hereof as reporting persons with respect to the securities described herein (the "Parallel Forms 4"). Information regarding these entities and individuals is included in this Form 4 for purposes of clarification and convenience only, and is duplicative of the information reported in the Parallel Forms 4. F3 · ownership.direct: The amount of securities shown in this row is owned directly by Akubra Investors, LLC ("Akubra"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.